Techno Drugs Past Earnings Performance
Past criteria checks 1/6
Techno Drugs's earnings have been declining at an average annual rate of -59.3%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 45.6% per year. Techno Drugs's return on equity is 7.5%, and it has net margins of 7.2%.
Key information
-59.3%
Earnings growth rate
-59.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -45.6% |
| Return on equity | 7.5% |
| Net Margin | 7.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Techno Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 2,733 | 196 | 628 | 0 |
| 30 Jun 22 | 5,029 | 480 | 905 | 0 |
Quality Earnings: TECHNODRUG has high quality earnings.
Growing Profit Margin: TECHNODRUG's current net profit margins (7.2%) are lower than last year (9.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TECHNODRUG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: TECHNODRUG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TECHNODRUG had negative earnings growth (-59.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.8%).
Return on Equity
High ROE: TECHNODRUG's Return on Equity (7.5%) is considered low.